选择性COX - 2抑制剂可联合化疗、内分泌治疗及生物治疗等，作为肿瘤治疗的辅助药物应用于临床，为乳腺癌的治疗提供一种新的途径。
Selective COX-2 inhibitors can combine with chemotherapy, endocrine therapy and biotherapy. It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.
目的探讨神经性厌食症患者的临床表现、内分泌功能改变和治疗方法。
Objective: to explore the symptoms of anorexia nervosa, the changes of function and treatment methods.
作者认为，HD—MA和HD—HPC作为第二线内分泌治疗手段，对于晚期、复发或难治性乳腺癌是安全、有效并有其独具的优点的。
In conclusion, HD-MA and HD-HPC have established a role as, second-line endocrine therapy or salvage measurement for the postmenopausal women with advanced, relapsed and refractory breast cancer.
病人和方法：符合这次多中心二期实验的病人患有转移性低分化神经内分泌癌，并且之前未接受任何治疗。
Patients and METHODS: Patients eligible for this multicenter, phase II trial had metastatic poorly differentiated neuroendocrine carcinoma and had received no previous treatment.
病人和方法：符合这次多中心二期实验的病人患有转移性低分化神经内分泌癌，并且之前未接受任何治疗。
Patients and METHODS: Patients eligible for this multicenter, phase II trial had metastatic poorly differentiated neuroendocrine carcinoma and had received no previous treatment.
应用推荐